126 related articles for article (PubMed ID: 21498735)
1. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Saif MW
Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
[TBL] [Abstract][Full Text] [Related]
2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.
Saif MW; Merikas I; Tsimboukis S; Syrigos K
JOP; 2008 May; 9(3):267-74. PubMed ID: 18469438
[TBL] [Abstract][Full Text] [Related]
5. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract][Full Text] [Related]
9. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Chang BW; Saif MW
JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-induced episcleritis in a patient with pancreatic cancer.
Shahrokni A; Matuszczak J; Rajebi MR; Saif MW
JOP; 2008 Mar; 9(2):216-9. PubMed ID: 18326933
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
12. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies with Erlotinib (Tarceva).
Akita RW; Sliwkowski MX
Semin Oncol; 2003 Jun; 30(3 Suppl 7):15-24. PubMed ID: 12840797
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib: the first biologic in the management of pancreatic cancer.
Saif MW
Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
Saif MW; Gnanaraj J
Cutan Ocul Toxicol; 2010 Mar; 29(1):62-6. PubMed ID: 19954400
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer.
Bao K; Li X; He X; Jian L
Clin Ther; 2021 Jun; 43(6):1107-1115. PubMed ID: 34059328
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
Mandalà M; Moro C; Labianca R; Ferretti G
J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
[No Abstract] [Full Text] [Related]
18. Erlotinib in pancreatic cancer: are tumor cells the (only) target?
Normanno N; De Luca A
J Clin Oncol; 2007 Dec; 25(36):5836-7. PubMed ID: 18089885
[No Abstract] [Full Text] [Related]
19. Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Ko AH
J Clin Oncol; 2023 Oct; 41(30):4711-4712. PubMed ID: 37847994
[No Abstract] [Full Text] [Related]
20. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
McCleary-Wheeler AL; Carr RM; Palmer SR; Smyrk TC; Allred JB; Almada LL; Tolosa EJ; Lamberti MJ; Marks DL; Borad MJ; Molina JR; Qi Y; Lingle WL; Grothey A; Pitot HC; Jatoi A; Northfelt DW; Bryce AH; McWilliams RR; Okuno SH; Haluska P; Kim GP; Colon-Otero G; Lowe VJ; Callstrom MR; Ma WW; Bekaii-Saab T; Hung MC; Erlichman C; Fernandez-Zapico ME
Pancreatology; 2020 Jan; 20(1):101-109. PubMed ID: 31787526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
